The benchmark S&P 500 index is way up over the past year, but some of its dividend-paying components haven't participated in the gains. Bristol Myers Squibb's dividend offers a high yield that could rise on the back of several new drugs with soaring sales.
Bristol-Myers Squibb-backed Zenas BioPharma has filed to go public in the United States, a regulatory filing showed on Thursday, underscoring improving investor appetite for new listings.
Bristol Myers' (BMY) application seeking approval for the Opdivo/Yervoy combo to treat unresectable hepatocellular carcinoma gets accepted for FDA review.
Bristol Myers' (BMY) application to expand Breyanzi's label for the treatment of adult patients with relapsed or refractory follicular lymphoma gets EMA validation.
Bristol Myers Squibb doesn't sell anti-obesity drugs, but it can keep raising its dividend payout without them. Shares of Dow Inc. offer a yield above 5%, and there's a good chance the company can begin raising its payout again.
Bristol Myers Squibb will face major losses of patent exclusivity by 2029. BMS has launched a number of brand-new approvals to replace older products.
Bristol Myers (BMY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Bristol Myers Squibb (BMY) or Vertex Pharmaceuticals (VRTX). But which of these two stocks is more attractive to value investors?
Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.
Bristol Myers' (BMY) impressive second-quarter results propelled the stock in the past month. However, we advise investors not to be over-optimistic at this point and look before they leap.
The concept of value stocks are easy to understand.
Investing in biotech stocks with promising pipelines has to be the most exciting area of the market. A successful drug approval can not only unveil a blockbuster treatment worth billions of dollars, but it can literally change people's lives for the better.